JP7462338B2 - Anti-fatigue - Google Patents
Anti-fatigue Download PDFInfo
- Publication number
- JP7462338B2 JP7462338B2 JP2022107500A JP2022107500A JP7462338B2 JP 7462338 B2 JP7462338 B2 JP 7462338B2 JP 2022107500 A JP2022107500 A JP 2022107500A JP 2022107500 A JP2022107500 A JP 2022107500A JP 7462338 B2 JP7462338 B2 JP 7462338B2
- Authority
- JP
- Japan
- Prior art keywords
- ornithine
- salt
- fatigue
- present
- hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000002929 anti-fatigue Effects 0.000 title description 53
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 50
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 46
- 229960003104 ornithine Drugs 0.000 claims description 46
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 44
- 150000003839 salts Chemical class 0.000 claims description 24
- 235000013305 food Nutrition 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 14
- 235000013361 beverage Nutrition 0.000 claims description 8
- GGTYBZJRPHEQDG-WCCKRBBISA-N (2s)-2,5-diaminopentanoic acid hydrochloride Chemical compound Cl.NCCC[C@H](N)C(O)=O GGTYBZJRPHEQDG-WCCKRBBISA-N 0.000 claims description 7
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 6
- 108010011485 Aspartame Proteins 0.000 claims description 6
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 6
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 6
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 6
- 239000000605 aspartame Substances 0.000 claims description 6
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 6
- 235000010357 aspartame Nutrition 0.000 claims description 6
- 229960003438 aspartame Drugs 0.000 claims description 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 5
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 4
- 239000013589 supplement Substances 0.000 claims description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
- 235000017471 coenzyme Q10 Nutrition 0.000 claims 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims 2
- 229940110767 coenzyme Q10 Drugs 0.000 claims 2
- 229960003624 creatine Drugs 0.000 claims 2
- 239000006046 creatine Substances 0.000 claims 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims 2
- 235000005911 diet Nutrition 0.000 claims 2
- 230000037213 diet Effects 0.000 claims 2
- 235000013325 dietary fiber Nutrition 0.000 claims 2
- 229960002885 histidine Drugs 0.000 claims 2
- 229920002674 hyaluronan Polymers 0.000 claims 2
- 229960003160 hyaluronic acid Drugs 0.000 claims 2
- 229960003244 ornithine hydrochloride Drugs 0.000 claims 2
- 150000008442 polyphenolic compounds Chemical class 0.000 claims 2
- 235000013824 polyphenols Nutrition 0.000 claims 2
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 claims 1
- IGGNJMAFVGRDPN-DNVVRKGNSA-N (2s,3s)-2-amino-3-methylpentanoic acid;(2s)-5-oxopyrrolidine-2-carboxylic acid Chemical compound CC[C@H](C)[C@H](N)C(O)=O.OC(=O)[C@@H]1CCC(=O)N1 IGGNJMAFVGRDPN-DNVVRKGNSA-N 0.000 claims 1
- MEJYXFHCRXAUIL-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;hydrate Chemical compound O.NC(=N)N(C)CC(O)=O MEJYXFHCRXAUIL-UHFFFAOYSA-N 0.000 claims 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 claims 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims 1
- 229930195722 L-methionine Natural products 0.000 claims 1
- 244000103635 Lyophyllum ulmarium Species 0.000 claims 1
- 235000015934 Lyophyllum ulmarium Nutrition 0.000 claims 1
- 239000005913 Maltodextrin Substances 0.000 claims 1
- 229920002774 Maltodextrin Polymers 0.000 claims 1
- 206010028629 Myoglobinuria Diseases 0.000 claims 1
- CBQJSKKFNMDLON-JTQLQIEISA-M N-acetyl-L-phenylalaninate Chemical compound CC(=O)N[C@H](C([O-])=O)CC1=CC=CC=C1 CBQJSKKFNMDLON-JTQLQIEISA-M 0.000 claims 1
- IHYJTAOFMMMOPX-LURJTMIESA-N N-acetyl-L-valine Chemical compound CC(C)[C@@H](C(O)=O)NC(C)=O IHYJTAOFMMMOPX-LURJTMIESA-N 0.000 claims 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims 1
- 244000168667 Pholiota nameko Species 0.000 claims 1
- 235000014528 Pholiota nameko Nutrition 0.000 claims 1
- 235000010575 Pueraria lobata Nutrition 0.000 claims 1
- 244000046146 Pueraria lobata Species 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- 235000013793 astaxanthin Nutrition 0.000 claims 1
- 239000001168 astaxanthin Substances 0.000 claims 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims 1
- 229940022405 astaxanthin Drugs 0.000 claims 1
- 150000005693 branched-chain amino acids Chemical class 0.000 claims 1
- 229940106189 ceramide Drugs 0.000 claims 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims 1
- 235000013351 cheese Nutrition 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 229960004826 creatine monohydrate Drugs 0.000 claims 1
- 229940109262 curcumin Drugs 0.000 claims 1
- 235000012754 curcumin Nutrition 0.000 claims 1
- 239000004148 curcumin Substances 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 229960000673 dextrose monohydrate Drugs 0.000 claims 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims 1
- PQGVTLQEKCJXKF-RGMNGODLSA-N ethyl (2s)-2-amino-3-methylbutanoate;hydron;chloride Chemical compound Cl.CCOC(=O)[C@@H](N)C(C)C PQGVTLQEKCJXKF-RGMNGODLSA-N 0.000 claims 1
- QQGRWNMNWONMOO-LEUCUCNGSA-N ethyl (2s,3s)-2-amino-3-methylpentanoate;hydron;chloride Chemical compound Cl.CCOC(=O)[C@@H](N)[C@@H](C)CC QQGRWNMNWONMOO-LEUCUCNGSA-N 0.000 claims 1
- 201000001505 hemoglobinuria Diseases 0.000 claims 1
- 229940049920 malate Drugs 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- 229940035034 maltodextrin Drugs 0.000 claims 1
- 229960004452 methionine Drugs 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 229940104261 taurate Drugs 0.000 claims 1
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims 1
- 229960002898 threonine Drugs 0.000 claims 1
- 229960004295 valine Drugs 0.000 claims 1
- 239000000052 vinegar Substances 0.000 claims 1
- 235000021419 vinegar Nutrition 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 description 52
- 239000004480 active ingredient Substances 0.000 description 27
- 206010016256 fatigue Diseases 0.000 description 23
- 241000196324 Embryophyta Species 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 17
- 229940024606 amino acid Drugs 0.000 description 17
- 150000001413 amino acids Chemical class 0.000 description 17
- 241000209094 Oryza Species 0.000 description 16
- 235000007164 Oryza sativa Nutrition 0.000 description 15
- 239000000463 material Substances 0.000 description 15
- 235000009566 rice Nutrition 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 229940088594 vitamin Drugs 0.000 description 13
- 229930003231 vitamin Natural products 0.000 description 13
- 235000013343 vitamin Nutrition 0.000 description 13
- 239000011782 vitamin Substances 0.000 description 13
- 239000004615 ingredient Substances 0.000 description 11
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 235000003599 food sweetener Nutrition 0.000 description 9
- 239000008187 granular material Substances 0.000 description 9
- 210000003098 myoblast Anatomy 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000003765 sweetening agent Substances 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- 230000003833 cell viability Effects 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 229910052500 inorganic mineral Inorganic materials 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000011707 mineral Substances 0.000 description 8
- 235000010755 mineral Nutrition 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 6
- 241000018646 Pinus brutia Species 0.000 description 6
- 235000011613 Pinus brutia Nutrition 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 6
- 150000003722 vitamin derivatives Chemical class 0.000 description 6
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 5
- 229930003779 Vitamin B12 Natural products 0.000 description 5
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 229960000304 folic acid Drugs 0.000 description 5
- 235000019152 folic acid Nutrition 0.000 description 5
- 239000011724 folic acid Substances 0.000 description 5
- -1 inorganic acid salts Chemical class 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 235000001968 nicotinic acid Nutrition 0.000 description 5
- 229960003512 nicotinic acid Drugs 0.000 description 5
- 239000011664 nicotinic acid Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 235000019163 vitamin B12 Nutrition 0.000 description 5
- 239000011715 vitamin B12 Substances 0.000 description 5
- 239000011701 zinc Substances 0.000 description 5
- 229910052725 zinc Inorganic materials 0.000 description 5
- 235000016804 zinc Nutrition 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229930003451 Vitamin B1 Natural products 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- 229920002770 condensed tannin Polymers 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 235000013922 glutamic acid Nutrition 0.000 description 4
- 239000004220 glutamic acid Substances 0.000 description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
- 229960000310 isoleucine Drugs 0.000 description 4
- 229960003646 lysine Drugs 0.000 description 4
- 229960003495 thiamine Drugs 0.000 description 4
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 4
- 235000010374 vitamin B1 Nutrition 0.000 description 4
- 239000011691 vitamin B1 Substances 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- 108010085443 Anserine Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- SLRNWACWRVGMKD-UHFFFAOYSA-N L-anserine Natural products CN1C=NC(CC(NC(=O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-UHFFFAOYSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 206010049565 Muscle fatigue Diseases 0.000 description 3
- 241001236212 Pinus pinaster Species 0.000 description 3
- 235000005105 Pinus pinaster Nutrition 0.000 description 3
- 241000210053 Potentilla elegans Species 0.000 description 3
- 229930003448 Vitamin K Natural products 0.000 description 3
- MYYIAHXIVFADCU-QMMMGPOBSA-N anserine Chemical compound CN1C=NC=C1C[C@H](NC(=O)CC[NH3+])C([O-])=O MYYIAHXIVFADCU-QMMMGPOBSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 3
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 3
- 230000002040 relaxant effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 235000019158 vitamin B6 Nutrition 0.000 description 3
- 239000011726 vitamin B6 Substances 0.000 description 3
- 235000019168 vitamin K Nutrition 0.000 description 3
- 239000011712 vitamin K Substances 0.000 description 3
- 150000003721 vitamin K derivatives Chemical class 0.000 description 3
- 229940011671 vitamin b6 Drugs 0.000 description 3
- 229940046010 vitamin k Drugs 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 208000019914 Mental Fatigue Diseases 0.000 description 2
- 235000005205 Pinus Nutrition 0.000 description 2
- 241000218602 Pinus <genus> Species 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 229940106587 pine bark extract Drugs 0.000 description 2
- 235000020741 pine bark extract Nutrition 0.000 description 2
- 235000021395 porridge Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- VSIVTUIKYVGDCX-UHFFFAOYSA-M sodium;4-[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].COC1=CC([N+]([O-])=O)=CC=C1[N+]1=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=NN1C1=CC=C([N+]([O-])=O)C=C1 VSIVTUIKYVGDCX-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 description 1
- XNWFXTOHNKPYMK-UHFFFAOYSA-N 3,3a,4,5,6,6a-hexahydrocyclopenta[c]dioxole Chemical class C1OOC2CCCC21 XNWFXTOHNKPYMK-UHFFFAOYSA-N 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 235000005638 Austrian pine Nutrition 0.000 description 1
- 241001481833 Coryphaena hippurus Species 0.000 description 1
- AHLPHDHHMVZTML-SCSAIBSYSA-N D-Ornithine Chemical compound NCCC[C@@H](N)C(O)=O AHLPHDHHMVZTML-SCSAIBSYSA-N 0.000 description 1
- 240000006055 Dacrydium cupressinum Species 0.000 description 1
- 235000018782 Dacrydium cupressinum Nutrition 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 125000000635 L-ornithyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 241000218652 Larix Species 0.000 description 1
- 235000005590 Larix decidua Nutrition 0.000 description 1
- 235000008565 Pinus banksiana Nutrition 0.000 description 1
- 244000019397 Pinus jeffreyi Species 0.000 description 1
- 235000013264 Pinus jeffreyi Nutrition 0.000 description 1
- 235000013697 Pinus resinosa Nutrition 0.000 description 1
- 235000008578 Pinus strobus Nutrition 0.000 description 1
- 235000008585 Pinus thunbergii Nutrition 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 235000014030 Podocarpus spicatus Nutrition 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 235000008446 instant noodles Nutrition 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229960005337 lysine hydrochloride Drugs 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000036997 mental performance Effects 0.000 description 1
- 229910052751 metal Chemical class 0.000 description 1
- 239000002184 metal Chemical class 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000010204 pine bark Nutrition 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 235000017985 rocky mountain lodgepole pine Nutrition 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- VRMHCMWQHAXTOR-CMOCDZPBSA-N sesamin Natural products C1=C2OCOC2=CC([C@@H]2OC[C@@]3(C)[C@H](C=4C=C5OCOC5=CC=4)OC[C@]32C)=C1 VRMHCMWQHAXTOR-CMOCDZPBSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 235000013570 smoothie Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 235000013547 stew Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000008256 whipped cream Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 229940120612 zinc gluconate 5 mg Drugs 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Description
本発明は、抗疲労剤に係り、詳しくは、オルニチン又はその塩(以下、単にオルニチン類ということがある)及び特定の他の成分を有効成分とする抗疲労剤に関する。 The present invention relates to an anti-fatigue agent, and more specifically, to an anti-fatigue agent containing ornithine or a salt thereof (hereinafter sometimes simply referred to as ornithines) and other specific ingredients as active ingredients.
近年の長時間労働や過度のストレスを受ける状況下においては、肉体的・精神的疲労が蓄積しやすく、これら疲労の疲労改善を目的とした薬剤等の開発が盛んに行われている。 In recent years, physical and mental fatigue can easily accumulate due to long working hours and excessive stress, and there has been active development of medicines and other products aimed at improving this fatigue.
例えば、オルニチンまたはその塩、およびグルタチオンまたはその塩を有効成分として含有する疲労軽減剤(特許文献1)や、特定の構造式で表されるセサミンなどのジオキサビシクロ〔3.3.0〕オクタン誘導体を有効成分とする抗疲労剤(特許文献2)が提案されている。 For example, a fatigue-reducing agent containing ornithine or a salt thereof, and glutathione or a salt thereof as active ingredients (Patent Document 1) and an anti-fatigue agent containing a dioxabicyclo[3.3.0]octane derivative such as sesamin represented by a specific structural formula as an active ingredient (Patent Document 2) have been proposed.
本発明の課題は、疲労軽減効果の高い抗疲労剤を提供することにある。 The objective of the present invention is to provide an anti-fatigue agent that is highly effective in reducing fatigue.
本発明者らは、オルニチンの疲労軽減効果について鋭意調査・研究したところ、オルニチンと特定の他の成分とを組み合わせることにより、高い疲労軽減効果が得られることを見いだし、本発明を完成するに至った。具体的には、オルニチンと、疲労軽減能がほとんどないか、その能力が小さい特定の他の成分を組み合わせることにより、疲労軽減能を相乗的に向上させることができることを見いだした。 The inventors conducted extensive research and studies into the fatigue-reducing effect of ornithine, and discovered that a high fatigue-reducing effect can be achieved by combining ornithine with other specific ingredients, leading to the completion of the present invention. Specifically, they discovered that by combining ornithine with other specific ingredients that have little or no fatigue-reducing ability, it is possible to synergistically improve the fatigue-reducing ability.
すなわち、本発明は、オルニチン又はその塩と、下記(a)~(d)からなる群より選ばれる少なくとも1種の成分とを有効成分として含有することを特徴とする抗疲労剤に関する。
(a)松、及び稲から選ばれる少なくとも1種の植物素材
(b)アスパルテーム、トレハロース、及び還元パラチノースから選ばれる少なくとも1種の甘味剤
(c)グルタミン、グルタミン酸、グリシン、ヒスチジン、イソロイシン、ロイシン、リジン、メチオニン、フェニルアラニン、チロシン、及びアンセリンから選ばれる少なくとも1種のアミノ酸類
(d)ビタミンB1、ビタミンB6、ビタミンB12、ビタミンE、ナイアシン、葉酸、ビタミンK、及び亜鉛から選ばれる少なくとも1種のビタミン・ミネラル類
That is, the present invention relates to an anti-fatigue agent characterized by containing ornithine or a salt thereof and at least one component selected from the group consisting of the following (a) to (d) as active ingredients:
(a) at least one plant material selected from pine and rice; (b) at least one sweetener selected from aspartame, trehalose, and reduced palatinose; (c) at least one amino acid selected from glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, tyrosine, and anserine; and (d) at least one vitamin and mineral selected from vitamin B1, vitamin B6, vitamin B12, vitamin E, niacin, folic acid, vitamin K, and zinc.
本発明の抗疲労剤は、オルニチン又はその塩と(a)~(d)からなる群より選ばれる少なくとも1種の成分とからなる有効成分を添加して得たものであってもよい。 The anti-fatigue agent of the present invention may be obtained by adding an active ingredient consisting of ornithine or a salt thereof and at least one component selected from the group consisting of (a) to (d).
また、本発明の抗疲労剤は、オルニチン又はその塩と他の有効成分との配合質量比が、0.5:1~70:1の範囲であることが好ましい。また、錠剤、カプセル剤、粉末剤、顆粒剤、又は液剤であることが好ましい。 The anti-fatigue agent of the present invention preferably has a mass ratio of ornithine or a salt thereof to other active ingredients in the range of 0.5:1 to 70:1. It is also preferable that the agent is in the form of a tablet, capsule, powder, granule, or liquid.
さらに、本発明は、上記抗疲労剤を摂取させることを特徴とする疲労軽減方法(ただし、医療行為を除く)に関する。 The present invention further relates to a method for reducing fatigue (excluding medical procedures) that comprises ingesting the above-mentioned anti-fatigue agent.
本発明の抗疲労剤によれば、高い疲労軽減効果を得ることができる。 The anti-fatigue agent of the present invention can provide a high fatigue reduction effect.
本発明の抗疲労剤は、オルニチン又はその塩と、下記(a)~(d)からなる群より選ばれる少なくとも1種の成分(以下、他成分ということがある)とを有効成分として含有することを特徴とする。 The anti-fatigue agent of the present invention is characterized by containing ornithine or a salt thereof and at least one component selected from the group consisting of the following (a) to (d) (hereinafter sometimes referred to as the other component) as active ingredients:
本発明の抗疲労剤は、肉体的な疲労、及び肉体的疲労に起因する精神的疲労を軽減することができるものであり、具体的には、疲労の予防、改善を行うことができる。すなわち、本発明の抗疲労剤を作業前に摂取することにより、摂取後の作業において疲労の発生が抑制される(疲れにくくする)疲労予防効果が得られると共に、作業後に摂取することにより、作業により生じた疲労を改善(回復)する疲労改善効果が得られる。また、睡眠中に筋肉疲労を軽減することにより、睡眠中のリラックス効果が得られる。 The anti-fatigue agent of the present invention can reduce physical fatigue and mental fatigue caused by physical fatigue, and specifically, can prevent and improve fatigue. That is, by taking the anti-fatigue agent of the present invention before working, a fatigue prevention effect is obtained in which the occurrence of fatigue is suppressed (making it difficult to get tired) during work after taking the agent, and by taking the agent after work, a fatigue improvement effect is obtained in which fatigue caused by work is improved (recovered). In addition, by reducing muscle fatigue during sleep, a relaxing effect during sleep can be obtained.
[オルニチン]
本発明の抗疲労剤の有効成分となるオルニチンとしては、L-オルニチンであってもよく、D-オルニチンであってもよいが、L-オルニチンであることが好ましい。オルニチンは、化学合成により得られたもの、発酵に得られたもの等、その製造方法は問わない。また、オルニチンの塩としては、薬学的に許容される塩であれば特に制限されるものではなく、例えば、無機酸塩、有機酸塩、金属塩を挙げることができる。オルニチンは、医薬品、試薬等として市販されており、これらの市販品を用いることができる。
[Ornithine]
Ornithine, which is the active ingredient of the anti-fatigue agent of the present invention, may be L-ornithine or D-ornithine, but is preferably L-ornithine. Ornithine may be obtained by chemical synthesis, fermentation, or any other method of production. In addition, the salt of ornithine is not particularly limited as long as it is a pharmacologic acceptable salt, and examples thereof include inorganic acid salts, organic acid salts, and metal salts. Ornithine is commercially available as a pharmaceutical product, a reagent, and the like, and these commercially available products can be used.
[他成分] [Other ingredients]
(a)植物素材
本発明の抗疲労剤においては、オルニチン又はその塩と共に、有効成分として、松、及び稲から選ばれる少なくとも1種の植物素材を用いることが好ましい。
(a) Plant Material In the anti-fatigue agent of the present invention, it is preferable to use at least one plant material selected from pine and rice together with ornithine or a salt thereof as an active ingredient.
これらの植物素材は、葉、茎、根、花、実、幹、枝等、植物のいずれの部位であってもよく、植物素材そのもの(乾燥物を含む)の他、その粉砕物、搾汁、抽出物等の植物素材処理物を用いることができる。粉砕物としては、粉末、顆粒等が挙げられる。絞汁や抽出物は、液状であってもよいが、ペースト状や乾燥粉末として用いることもできる。抽出物は、適当な溶媒を用いて抽出することに得ることができ、溶媒としては、例えば、水(熱水)、エタノール、含水エタノールを用いることができる。これらの植物素材は、市販されているものを使用することができる。 These plant materials may be any part of the plant, such as leaves, stems, roots, flowers, fruits, trunks, branches, etc., and in addition to the plant materials themselves (including dried products), processed plant materials such as crushed products, juice, extracts, etc. can be used. Examples of crushed products include powders and granules. The juice and extracts may be in liquid form, but can also be used in the form of a paste or dried powder. Extracts can be obtained by extraction using a suitable solvent, and examples of the solvent that can be used include water (hot water), ethanol, and aqueous ethanol. These plant materials can be commercially available.
松としては、例えば、フランス海岸松(Pinus Martima)、カラマツ、クロマツ、アカマツ等を挙げることができ、これらの中でも、プロアントシアニジンが豊富に含まれるフランス海岸松(Pinus Martima)が好ましい。本発明の植物素材として用いる部位としては樹皮が好ましく、この松樹皮から得られる抽出物が特に好ましい。この抽出物には、プロアントシアニジンの他、オリゴメリックプロアントシアニジンが高濃度で含まれており、例えば、抽出物の乾燥質量に対してオリゴメリックプロアントシアニジンを20質量%以上含むものが好ましい。 Examples of pines include French maritime pine (Pinus Martima), larch, black pine, red pine, etc., and among these, French maritime pine (Pinus Martima), which is rich in proanthocyanidins, is preferred. The part of the plant used as the plant material of the present invention is preferably the bark, and an extract obtained from this pine bark is particularly preferred. This extract contains high concentrations of oligomeric proanthocyanidins in addition to proanthocyanidins, and preferably contains, for example, 20% by mass or more of oligomeric proanthocyanidins based on the dry mass of the extract.
稲は、イネ科イネ属の植物である。本発明の植物素材として用いる部位としては、玄米の外皮や胚が好ましく、具体的には、玄米を精白する際に副産物として得られる米ぬかを用いることが好ましい。稲の種類としては、特に制限はなく、ジャポニカ種、インディカ種等を挙げることができる。 Rice is a plant of the genus Oryza in the family Poaceae. The parts of the plant used as the plant material of the present invention are preferably the outer husk and embryo of brown rice, and more specifically, it is preferable to use rice bran, which is obtained as a by-product when brown rice is polished. There are no particular limitations on the type of rice, and examples include the japonica and indica varieties.
(b)甘味剤
本発明の抗疲労剤においては、オルニチン又はその塩と共に、有効成分として、アスパルテーム、トレハロース、及び還元パラチノースから選ばれる少なくとも1種の甘味剤を用いることが好ましい。本発明の甘味剤は、甘味を呈するものを意味し、甘味料としての使用目的に限定されない。
(b) Sweetener In the anti-fatigue agent of the present invention, it is preferable to use at least one sweetener selected from aspartame, trehalose, and reduced palatinose as an active ingredient together with ornithine or a salt thereof. The sweetener of the present invention means one that exhibits sweetness, and is not limited to the purpose of use as a sweetener.
(c)アミノ酸類
本発明の抗疲労剤においては、オルニチン又はその塩と共に、有効成分として、グルタミン、グルタミン酸、グリシン、ヒスチジン、イソロイシン、ロイシン、リジン、メチオニン、フェニルアラニン、チロシン、及びアンセリンから選ばれる少なくとも1種のアミノ酸類(塩を含む)を用いることが好ましい。塩としては、例えば、ナトリウム塩、塩酸塩等を挙げることができる。
(c) Amino acids In the anti-fatigue agent of the present invention, it is preferable to use at least one amino acid (including a salt) selected from glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, tyrosine, and anserine as an active ingredient together with ornithine or a salt thereof. Examples of the salt include sodium salt and hydrochloride.
(d)ビタミン・ミネラル類
本発明の抗疲労剤においては、オルニチン又はその塩と共に、有効成分として、ビタミンB1、ビタミンB6、ビタミンB12、ビタミンE、ナイアシン、葉酸、ビタミンK、及び亜鉛から選ばれる少なくとも1種のビタミン・ミネラル類を用いることが好ましい。なお、本発明のミネラル類としての亜鉛は、亜鉛を含む化合物の形態を含む。
(d) Vitamins and Minerals In the anti-fatigue agent of the present invention, it is preferable to use, together with ornithine or a salt thereof, at least one vitamin and mineral selected from vitamin B1, vitamin B6, vitamin B12, vitamin E, niacin, folic acid, vitamin K, and zinc as an active ingredient. Note that zinc as a mineral of the present invention includes the form of a compound containing zinc.
本発明の抗疲労剤は、オルニチン又はその塩と所定の他成分とを含有し、抗疲労に用いられる点において、製品として他の製品と区別することができるものであれば特に制限されるものではなく、例えば、本発明に係る製品の本体、包装、説明書、宣伝物のいずれかに抗疲労の機能がある旨を表示したものが本発明の範囲に含まれる。例えば、医薬品(医薬部外品を含む)や、特定保健用食品、栄養機能食品、機能性表示食品等の所定機関より効能の表示が認められた機能性食品などのいわゆる健康食品や、飼料等を挙げることができる。いわゆる健康食品においては、「続く疲れに」、「毎日の疲れに」、「肉体的、精神的な高いパフォーマンスをサポート」、「疲れの改善」、「ストレスの改善」、「睡眠の改善」、「眠りを良くする」、「疲れやすい方に」等を表示したものを例示することができる。本発明の抗疲労剤は、上記の効果が気になる人であれば性別や年齢に関係なく摂取することができるが、本発明の抗疲労剤の効果をより有効に享受することができることから、疾病者を除く健常者が摂取することが望ましい。また、睡眠中に筋肉疲労を軽減することにより、睡眠中のリラックス効果が得られることから、夜に摂取することが望ましく、睡眠前に摂取することがさらに望ましい。 The anti-fatigue agent of the present invention is not particularly limited as long as it contains ornithine or a salt thereof and a specified other ingredient, and can be distinguished from other products in terms of its use for anti-fatigue. For example, the scope of the present invention includes products that display the anti-fatigue function on the main body, packaging, instructions, or advertising materials of the product according to the present invention. Examples of the anti-fatigue agent include so-called health foods such as pharmaceuticals (including quasi-drugs), functional foods such as specified health foods, nutritional functional foods, and functional foods whose efficacy has been approved by a specified organization, and feed. Examples of so-called health foods include those that display the following: "For continued fatigue," "For daily fatigue," "Supports high physical and mental performance," "Improves fatigue," "Improves stress," "Improves sleep," "Improves sleep," and "For those who get tired easily." The anti-fatigue agent of the present invention can be taken by anyone who is concerned about the above effects, regardless of gender or age, but it is preferable for healthy people, excluding those with illnesses, to take it in order to enjoy the effects of the anti-fatigue agent of the present invention more effectively. In addition, since a relaxing effect during sleep can be obtained by reducing muscle fatigue during sleep, it is preferable to take it at night, and even more preferable to take it before sleep.
本発明の抗疲労剤の形態としては、例えば、錠剤、カプセル剤、粉末剤、顆粒剤、液剤、粒状剤、棒状剤、板状剤、ブロック状剤、固形状剤、丸状剤、ペースト状剤、クリーム状剤、カプレット状剤、ゲル状剤、チュアブル状剤、スティック状剤等を挙げることができる。これらの中でも、錠剤、カプセル剤、粉末剤、顆粒剤、液剤の形態が特に好ましい。具体的には、サプリメントや、ペットボトル、缶、瓶等に充填された容器詰飲料や、水(湯)、牛乳、果汁、青汁等に溶解して飲むためのインスタント粉末飲料、インスタント顆粒飲料を例示することができる。これらは食事の際などに手軽に飲用しやすく、また嗜好性を高めることができるという点で好ましい。 Examples of the form of the anti-fatigue agent of the present invention include tablets, capsules, powders, granules, liquids, granules, rods, plates, blocks, solids, pills, pastes, creams, caplets, gels, chewables, and sticks. Among these, tablets, capsules, powders, granules, and liquids are particularly preferred. Specific examples include supplements, packaged beverages filled in PET bottles, cans, bottles, and the like, and instant powdered beverages and instant granular beverages that are dissolved in water (hot water), milk, fruit juice, green juice, and the like before drinking. These are preferred because they are easy to drink during meals and can increase palatability.
本発明の抗疲労剤におけるオルニチン及び他成分(有効成分)の含有量としては、その効果の奏する範囲で適宜含有させればよい。 The content of ornithine and other ingredients (active ingredients) in the anti-fatigue agent of the present invention may be appropriately determined within the range in which the effect is exhibited.
一般的には、本発明の抗疲労剤が医薬品やサプリメント(錠剤,カプセル剤)の場合には、有効成分が乾燥質量換算で全体の0.01~100質量%含まれていることが好ましく、0.1~85質量%含まれていることがより好ましく、0.5~70質量%含まれていることがさらに好ましい。 In general, when the anti-fatigue agent of the present invention is a medicine or supplement (tablet, capsule), the active ingredient is preferably contained in an amount of 0.01 to 100% by mass, more preferably 0.1 to 85% by mass, and even more preferably 0.5 to 70% by mass, of the total mass calculated on a dry weight basis.
本発明の抗疲労剤が容器詰飲料(液剤)である場合には、有効成分が乾燥質量換算で全体の0.01~10質量%含まれていることが好ましく、0.03~6質量%含まれていることがより好ましく、0.05~4質量%含まれていることがさらに好ましい。 When the anti-fatigue agent of the present invention is a packaged beverage (liquid preparation), the active ingredient is preferably contained in an amount of 0.01 to 10% by mass, more preferably 0.03 to 6% by mass, and even more preferably 0.05 to 4% by mass, of the total amount calculated on a dry weight basis.
また、本発明の抗疲労剤がインスタント粉末飲料(粉末剤)、インスタント顆粒飲料(顆粒剤)である場合には、有効成分が乾燥質量換算で全体の1~100質量%含まれていることが好ましく、5~90質量%含まれていることがより好ましく、10~80質量%含まれていることがさらに好ましい。 When the anti-fatigue agent of the present invention is an instant powdered beverage (powder) or an instant granular beverage (granule), the active ingredient is preferably contained in an amount of 1 to 100% by mass, more preferably 5 to 90% by mass, and even more preferably 10 to 80% by mass, of the total amount calculated on a dry weight basis.
本発明の効果をより有効に発揮させるためには、有効成分が乾燥質量換算で本発明の抗疲労剤全体(水分を除く)の80%以上含まれていることが好ましく、90%以上含まれていることがより好ましく、95%以上含まれていることがさらに好ましく、100%であることが特に好ましい。さらに、本発明の抗疲労剤が成分(a)~(d)のいずれかを含有する場合、その含有される成分は、本発明における有効成分のみで構成されることが好ましい。すなわち、本発明の抗疲労剤が例えば成分(a)(植物素材)を含む場合には、松、稲以外の植物素材を含まないように構成することが好ましい。 In order to more effectively exert the effects of the present invention, the active ingredient is preferably contained in an amount of 80% or more of the entire anti-fatigue agent of the present invention (excluding water) calculated on a dry mass basis, more preferably 90% or more, even more preferably 95% or more, and particularly preferably 100%. Furthermore, when the anti-fatigue agent of the present invention contains any of components (a) to (d), it is preferable that the contained components consist only of the active ingredient of the present invention. In other words, when the anti-fatigue agent of the present invention contains, for example, component (a) (a plant material), it is preferable that the composition does not contain any plant material other than pine or rice.
本発明の抗疲労剤の摂取量としては特に制限はないが、本発明の効果をより顕著に発揮させる観点から、1日当たりの有効成分の摂取量が、100mg/日以上となるように摂取することが好ましく、200mg/日以上となるように摂取することがより好ましく、300mg/日以上となるように摂取することがさらに好ましい。その上限は特に制限されないが、例えば、2g/日であり、好ましくは3g/日である。本発明の抗疲労剤は、1日の摂取量が前記摂取量となるように、1つの容器に、又は例えば2~3の複数の容器に分けて、1日分として収容することができる。 There is no particular limit to the amount of intake of the anti-fatigue agent of the present invention, but from the viewpoint of more significantly exerting the effects of the present invention, it is preferable to take the active ingredient so that the daily intake is 100 mg/day or more, more preferably 200 mg/day or more, and even more preferably 300 mg/day or more. The upper limit is not particularly limited, but is, for example, 2 g/day, and preferably 3 g/day. The anti-fatigue agent of the present invention can be stored as a daily dose in one container or divided into multiple containers, for example, 2 to 3, so that the daily intake is the above-mentioned amount.
オルニチン類及び他成分の配合質量比としては、乾燥質量換算で、0.5:1~70:1の範囲であることが好ましく、0.75:1~60:1の範囲であることがより好ましく、1:1~60:1の範囲であることがさらに好ましく、1:1~50:1の範囲であることが特に好ましい。オルニチン類及び他成分の配合比が、上記範囲であることにより、本発明の効果をより有効に発揮することができる。 The blending mass ratio of ornithines and other components is preferably in the range of 0.5:1 to 70:1, more preferably in the range of 0.75:1 to 60:1, even more preferably in the range of 1:1 to 60:1, and particularly preferably in the range of 1:1 to 50:1, in terms of dry mass. By having the blending ratio of ornithines and other components in the above range, the effects of the present invention can be more effectively exhibited.
本発明の抗疲労剤は、必要に応じて、経口用として許容される添加剤や、有効成分以外の成分を添加して、公知の製剤方法によって製造することができる。 The anti-fatigue agent of the present invention can be produced by known formulation methods by adding, as necessary, additives acceptable for oral use and ingredients other than the active ingredient.
また、本発明の抗疲労剤としては、有効成分を含有する抗疲労用食品の他、食品に対して有効成分を添加して得た抗疲労用食品を挙げることができ、例えば、通常の食品(天然の食品を含む)に比して本発明の有効成分含有量を増加させた食品や、本発明の有効成分を通常含まない食品に対して有効成分を添加したものを挙げることができる。有効成分の添加は、それぞれの成分を別々に添加してもよいし、同時に添加してもよく、また、有効成分以外の他の成分と共に添加してもよい。 The anti-fatigue agent of the present invention may be an anti-fatigue food containing the active ingredient, or an anti-fatigue food obtained by adding the active ingredient to a food, such as a food in which the content of the active ingredient of the present invention is increased compared to normal foods (including natural foods), or a food that does not normally contain the active ingredient of the present invention to which the active ingredient has been added. The active ingredients may be added separately or simultaneously, or together with other ingredients other than the active ingredient.
本発明の抗疲労用食品としては、例えば、炭酸飲料、栄養飲料、果実飲料、乳酸飲料、スムージー、青汁等の飲料;アイスクリーム、アイスシャーベット、かき氷等の冷菓;そば、うどん、はるさめ、中華麺、即席麺等の麺類;飴、キャンディー、ガム、チョコレート、錠菓、スナック菓子、ビスケット、ゼリー、ジャム、クリーム、焼き菓子、パン等の菓子類;かまぼこ、ハム、ソーセージ等の水産・畜産加工食品;加工乳、発酵乳、ヨーグルト等の乳製品;サラダ油、てんぷら油、マーガリン、マヨネーズ、ショートニング、ホイップクリーム、ドレッシング等の油脂及びその加工食品;ソース、醤油等の調味料;カレー、シチュー、親子丼、お粥、雑炊、中華丼、かつ丼、天丼、牛丼、ハヤシライス、オムライス、おでん、マーボドーフ、餃子、シューマイ、ハンバーグ、ミートボール、各種ソース、各種スープ等のレトルトパウチ食品などを挙げることができる。 Examples of the anti-fatigue foods of the present invention include beverages such as carbonated drinks, nutritional drinks, fruit drinks, lactic acid drinks, smoothies, and green juice; frozen desserts such as ice cream, ice sherbet, and shaved ice; noodles such as soba, udon, harusame, Chinese noodles, and instant noodles; sweets such as candy, candy, gum, chocolate, tablet sweets, snacks, biscuits, jellies, jams, creams, baked goods, and bread; processed seafood and livestock foods such as kamaboko, ham, and sausages; processed milk, fermented milk, Examples include dairy products such as yogurt; fats and oils such as salad oil, tempura oil, margarine, mayonnaise, shortening, whipped cream, dressing, and processed foods; seasonings such as sauces and soy sauce; retort pouch foods such as curry, stew, oyakodon, rice porridge, porridge, Chinese rice bowl, katsudon, tempura bowl, beef bowl, hayashi rice, omelet rice, oden, mapo dolphin, gyoza, shumai, hamburger steak, meatballs, various sauces, and various soups.
本発明の疲労軽減方法としては、上記説明した本発明の抗疲労剤を摂取させることを特徴とするが、医療行為は含まれない。本発明の抗疲労剤は、上記の効果が気になる人であれば性別や年齢に関係なく摂取させることができるが、本発明の抗疲労剤の効果をより有効に享受することができることから、疾病者を除く健常者に摂取させることが望ましい。また、睡眠中に筋肉疲労を軽減することにより、睡眠中のリラックス効果が得られることから、夜に摂取させることが望ましく、睡眠前に摂取させることがさらに望ましい。本発明の方法としては、例えば、レストラン等の飲食店において、本発明の抗疲労用食品を提供することにより、疲労軽減を図る方法を挙げることができる。 The fatigue reduction method of the present invention is characterized by ingesting the anti-fatigue agent of the present invention described above, but does not include medical procedures. The anti-fatigue agent of the present invention can be ingested by anyone who is concerned about the above-mentioned effects, regardless of gender or age, but it is preferable for healthy people, excluding those with illnesses, to ingest the agent, since the effects of the anti-fatigue agent of the present invention can be enjoyed more effectively. In addition, since reducing muscle fatigue during sleep provides a relaxing effect during sleep, it is preferable to ingest the agent at night, and even more preferable to ingest the agent before sleep. An example of the method of the present invention is a method of reducing fatigue by providing the anti-fatigue food of the present invention in a restaurant or other eating establishment.
以下、本発明を実施例に基づき説明する。
[実施例1]
(1)マウス筋芽細胞株C2C12を、5×103cells/wellとなるよう96well plateへ播種した。
(2)一晩、前培養し、培養上清除去後、下記表1及び表2に示すようにサンプル添加を行った。
The present invention will be described below with reference to examples.
[Example 1]
(1) Mouse myoblast cell line C2C12 was seeded into a 96-well plate at 5×10 3 cells/well.
(2) After pre-incubation overnight, the culture supernatant was removed and samples were added as shown in Tables 1 and 2 below.
各サンプルは、以下のように調製した。
各サンプルを5mg/mL(もしくは1.28mg/mL)となるよう10%FBS-DMEMへ溶解し、1h転倒撹拌後、フィルタリングを行ったものを原液とした。ただし、疎水性サンプルは、50mg/mLとなるようDMSOへ溶解したものを原液とした。
Each sample was prepared as follows.
Each sample was dissolved in 10% FBS-DMEM to a concentration of 5 mg/mL (or 1.28 mg/mL), stirred by inversion for 1 hour, and filtered to prepare a stock solution. However, the hydrophobic sample was dissolved in DMSO to a concentration of 50 mg/mL to prepare a stock solution.
調製した原液を10%FBS-DMEMにてさらに希釈し、目的の終濃度の2倍濃度となるよう調整した。疎水性サンプルは、目的の終濃度の2倍濃度かつ1%DMSO-10%FBS-DMEMとなるよう調整した。 The prepared stock solution was further diluted with 10% FBS-DMEM to adjust the concentration to twice the desired final concentration. The hydrophobic sample was adjusted to twice the desired final concentration and to 1% DMSO-10% FBS-DMEM.
オルニチンについては、市販されるL-オルニチン塩酸塩を用いた。オルニチンと共に用いる他成分としては、表3~表6に示す物質を用いた。 For ornithine, commercially available L-ornithine hydrochloride was used. As other ingredients used together with ornithine, the substances shown in Tables 3 to 6 were used.
(3)サンプル添加より24時間後、Cell Counting Kit-8を用いて細胞生存率を測定した。この際、DMEM培地:WST-8溶液=20:1となるよう試薬調整を行った。 (3) 24 hours after the addition of the samples, cell viability was measured using Cell Counting Kit-8. The reagents were adjusted so that the ratio of DMEM medium to WST-8 solution was 20:1.
培養上清除去後、PBSにて各wellを1回洗浄し、PBSを除去した後、上記WST-8調製液を150μLずつ分注した。発色次第(約15分後)、450nmの吸光度を測定した。 After removing the culture supernatant, each well was washed once with PBS, and after removing the PBS, 150 μL of the above WST-8 preparation solution was dispensed into each well. As soon as color developed (approximately 15 minutes later), the absorbance at 450 nm was measured.
その結果を表3~表6、及び図1~図8に示す。図中の各グラフは、左から、「コントロール(添加なし)」、「オルニチン(O)の単独添加」、「他成分の単独添加」、「オルニチン+他成分添加」の結果を表す。また、グラフ下部の説明における数値は、サンプル濃度を示し、例えば、図1の左のグラフの「O_0.25」は、オルニチン0.25(μg/mL)を示す。添加成分の濃度単位は、すべてのグラフにおいて、μg/mLである。 The results are shown in Tables 3 to 6 and Figures 1 to 8. The graphs in the figures show, from left to right, the results for "control (no addition)", "ornithine (O) added alone", "other components added alone", and "ornithine + other components added". The numbers in the explanations below the graphs indicate the sample concentrations; for example, "O_0.25" in the graph on the left of Figure 1 indicates ornithine 0.25 (μg/mL). The concentration units for added components are μg/mL in all graphs.
松については、フランス海岸松の樹皮の熱水抽出物(乾燥粉末)を用いた。
稲(米ぬか)については、市販品を用いた。
ヨモギについては、生葉の微粉砕末を用いた。
For pine, a hot water extract (dried powder) of French maritime pine bark was used.
For rice (rice bran), a commercially available product was used.
For mugwort, finely ground fresh leaves were used.
表3~表6、及び図1~図8に示すように、オルニチンと、本発明の特定の他成分とを組み合わせることにより、筋細胞が相乗的に活発化した。したがって、本発明の抗疲労剤によれば、疲労をより有効に軽減することができる。 As shown in Tables 3 to 6 and Figures 1 to 8, muscle cells were activated synergistically by combining ornithine with other specific components of the present invention. Therefore, the anti-fatigue agent of the present invention can more effectively alleviate fatigue.
[実施例2](錠剤の製造)
下記成分からなるタブレットを製造した。
[Example 2] (Preparation of tablets)
Tablets were prepared consisting of the following ingredients:
L-オルニチン塩酸塩 130mg(オルニチンとして100mg)
フラクトオリゴ糖 20mg
松樹皮抽出物 10mg
アルギニン 20mg
イソロイシン 5mg
ロイシン 5mg
リジン 2mg
ビタミンE 1mg
二酸化ケイ素 30mg
シェラック 20mg
L-ornithine hydrochloride 130mg (100mg as ornithine)
Fructooligosaccharides 20mg
Pine bark extract 10mg
Arginine 20mg
Isoleucine 5mg
Leucine 5mg
Lysine 2mg
Vitamin E 1mg
Silicon dioxide 30mg
Shellac 20mg
上記錠剤は、一日に5~10粒を噛まずに水と共に服用する。 Take 5 to 10 tablets a day with water without chewing.
[実施例3](カプセル剤の製造)
下記混合物400mgをソフトカプセルに封入し、カプセル剤を製造した。
[Example 3] (Production of capsules)
400 mg of the following mixture was encapsulated in a soft capsule to prepare a capsule formulation.
L-オルニチン塩酸塩 260mg(オルニチンとして200mg)
アルギニン 60mg
リジン 8mg
葉酸 10mg
ビタミンB1 10mg
ナイアシン 10mg
グリセリン脂肪酸エステル 5mg
二酸化ケイ素 37mg
L-ornithine hydrochloride 260mg (200mg as ornithine)
Arginine 60mg
Lysine 8mg
Folic acid 10mg
Vitamin B1 10mg
Niacin 10mg
Glycerin fatty acid ester 5mg
Silicon dioxide 37mg
上記カプセル剤は、一日に5粒を噛まずに水と共に服用する。 Take 5 capsules a day with water without chewing.
[実施例4](顆粒剤の製造)
下記成分を混合して常法により顆粒剤(3000mg)を製造した。
[Example 4] (Preparation of granules)
The following ingredients were mixed and prepared into granules (3,000 mg) in a conventional manner.
L-オルニチン塩酸塩 2600mg(オルニチンとして2000mg)
米ぬか抽出物 200mg
グルタミン 60mg
グルタミン酸 40mg
ビタミンB12 10mg
グルコン酸亜鉛 5mg
乳糖 50mg
難消化性デキストリン 25mg
ショ糖脂肪酸エステル 10mg
L-ornithine hydrochloride 2600mg (2000mg as ornithine)
Rice bran extract 200mg
Glutamine 60mg
Glutamic acid 40mg
Vitamin B12 10mg
Zinc gluconate 5mg
Lactose 50mg
Resistant dextrin 25mg
Sucrose fatty acid ester 10mg
上記顆粒剤は、一日に1包を水などと共に服用する。 Take one packet of the above granules daily with water etc.
[実施例5](液剤の製造)
下記成分からなる液剤(100mL)を製造した。
[Example 5] (Production of liquid formulation)
A solution (100 mL) consisting of the following components was prepared.
アスパルテーム 500mg
トレハロース 400mg
L-オルニチン塩酸塩 400mg
松樹皮抽出物 100mg
ナイアシン 60mg
葉酸 50mg
ビタミンC 50mg
ビタミンB12 30mg
クエン酸 20mg
香料 適量
水 残部
Aspartame 500mg
Trehalose 400mg
L-ornithine hydrochloride 400mg
Pine bark extract 100mg
Niacin 60mg
Folic acid 50mg
Vitamin C 50mg
Vitamin B12 30mg
Citric acid 20mg
Fragrance Appropriate amount of water Remainder
本発明の抗疲労剤は、疲労軽減効果を有し、経口剤として用いることができることから、本発明の産業上の有用性は高い。 The anti-fatigue agent of the present invention has a fatigue-reducing effect and can be used as an oral preparation, so the present invention is highly useful industrially.
Claims (3)
(1)デキストロース一水和物、マルトデキストリン、クレアチン一水和物、リンゴ酸クレアチン、タウリン酸クレアチン、L-リジン塩酸塩、N-アセチル-L-バリン、L-バリンα-ケトグルタル酸塩、L-バリンエチルエステル塩酸塩、L-イソロイシンピログルタミン酸塩、L-イソロイシンエチルエステル塩酸塩、N-アセチル-L-フェニルアラニン、L-スレオニン、L-ヒスチジン、L-ヒスチジンα-ケトグルタル酸塩、及びL-メチオニンを含有する筋肉増強用経口組成物
(2)コエンザイムQ10、ヒアルロン酸、オルニチン塩酸塩、ポリフェノール及び食物繊維を含有するダイエット用飲料
(3)オルニチン又はその塩と、アスパルテームと、酢とを含有する経口組成物 A food composition comprising ornithine or a salt thereof and aspartame (excluding the oral compositions (1) to (3) below).
(1) An oral composition for muscle building containing dextrose monohydrate, maltodextrin, creatine monohydrate, creatine malate, creatine taurate, L-lysine hydrochloride, N-acetyl-L-valine, L-valine α-ketoglutarate, L-valine ethyl ester hydrochloride, L-isoleucine pyroglutamate, L-isoleucine ethyl ester hydrochloride, N-acetyl-L-phenylalanine, L-threonine, L-histidine, L-histidine α-ketoglutarate, and L-methionine. (2) A diet drink containing coenzyme Q10, hyaluronic acid, ornithine hydrochloride, polyphenols, and dietary fiber. (3) An oral composition containing ornithine or a salt thereof, aspartame, and vinegar.
(1)アスタキサンチン、システインペプチド、ビタミンC及びセラミドを含有する美容用飲料
(2)オルニチンを含有するチーズ
(3)分岐鎖アミノ酸又はその塩と、オルニチン又はその塩と、グルタミン又はその塩と、トレハロースとを含有するヘモグロビン尿症又はミオグロビン尿症の予防又は治療用経口組成物
(4)ナメコを含有する食品組成物
(5)ブナシメジを含有する食品組成物 A food composition comprising ornithine or a salt thereof and trehalose (excluding the oral compositions (1) to ( 5 ) below).
(1) A cosmetic beverage containing astaxanthin, cysteine peptide, vitamin C and ceramide. (2) A cheese containing ornithine. (3) An oral composition for preventing or treating hemoglobinuria or myoglobinuria containing a branched chain amino acid or a salt thereof, ornithine or a salt thereof, glutamine or a salt thereof, and trehalose.
(4) Food composition containing nameko
(5) Food composition containing Bunashimeji
(1)オルニチン、クルクミン及び葛の花を含有するサプリメント
(2)コエンザイムQ10、ヒアルロン酸、オルニチン塩酸塩、ポリフェノール及び食物繊維を含有するダイエット用飲料
A food composition comprising ornithine or a salt thereof and reduced palatinose (excluding the oral compositions of (1) and (2) below).
(1) A supplement containing ornithine, curcumin and kudzu flowers. (2) A diet drink containing coenzyme Q10, hyaluronic acid, ornithine hydrochloride, polyphenols and dietary fiber.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022107500A JP7462338B2 (en) | 2021-01-07 | 2022-07-04 | Anti-fatigue |
JP2024039547A JP2024061831A (en) | 2021-01-07 | 2024-03-14 | Anti-fatigue |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021001190A JP2021050244A (en) | 2021-01-07 | 2021-01-07 | Anti-fatigue agent |
JP2022107500A JP7462338B2 (en) | 2021-01-07 | 2022-07-04 | Anti-fatigue |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021001190A Division JP2021050244A (en) | 2021-01-07 | 2021-01-07 | Anti-fatigue agent |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2024039547A Division JP2024061831A (en) | 2021-01-07 | 2024-03-14 | Anti-fatigue |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022121730A JP2022121730A (en) | 2022-08-19 |
JP7462338B2 true JP7462338B2 (en) | 2024-04-05 |
Family
ID=75157080
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021001190A Pending JP2021050244A (en) | 2021-01-07 | 2021-01-07 | Anti-fatigue agent |
JP2022107500A Active JP7462338B2 (en) | 2021-01-07 | 2022-07-04 | Anti-fatigue |
JP2024039547A Pending JP2024061831A (en) | 2021-01-07 | 2024-03-14 | Anti-fatigue |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021001190A Pending JP2021050244A (en) | 2021-01-07 | 2021-01-07 | Anti-fatigue agent |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2024039547A Pending JP2024061831A (en) | 2021-01-07 | 2024-03-14 | Anti-fatigue |
Country Status (1)
Country | Link |
---|---|
JP (3) | JP2021050244A (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007000985A1 (en) | 2005-06-27 | 2007-01-04 | Kyowa Hakko Kogyo Co., Ltd. | Prophylactic or therapeutic composition for hemoglobinuria or myoglobinuria |
JP2008073007A (en) | 2006-09-25 | 2008-04-03 | Kyowa Hakko Kogyo Co Ltd | Vinegar acidity suppressing method |
JP2011139687A (en) | 2010-01-08 | 2011-07-21 | Kirin Holdings Co Ltd | Highly flavored ornithine-containing alcohol-free malt beverage |
JP2011147419A (en) | 2010-01-25 | 2011-08-04 | Kirin Kyowa Fd Kk | Ornithine-containing instant dried rice gruel |
JP2014054234A (en) | 2012-09-14 | 2014-03-27 | Daicel Corp | Composition containing ornithine and equol |
JP2015050991A (en) | 2013-08-05 | 2015-03-19 | 株式会社ニッセン | Health supplement |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0757168B2 (en) * | 1991-04-19 | 1995-06-21 | 市浦村商工会 | Method for producing shijimi extract |
JP2713392B2 (en) * | 1994-01-19 | 1998-02-16 | 義秀 萩原 | Production method of Shijimi extract |
JP4699901B2 (en) * | 2003-09-02 | 2011-06-15 | ジェレックスインターナショナル株式会社 | Dietary additive with body fat metabolism function and combustion energy utilization function |
CN101766637B (en) * | 2008-12-31 | 2012-08-29 | 克科 | Composite for disintoxicating and sobering |
CN101953825B (en) * | 2010-09-25 | 2012-10-10 | 万红贵 | Anti-alcohol composition and application thereof in preparation of health-care products |
JP2014159381A (en) * | 2013-02-19 | 2014-09-04 | Kyowa Hakko Bio Co Ltd | Ornithine-containing composition for improving body composition |
CN103622121B (en) * | 2013-11-13 | 2015-09-02 | 精晶药业股份有限公司 | A kind of solid beverage containing glutamine dipeptide |
-
2021
- 2021-01-07 JP JP2021001190A patent/JP2021050244A/en active Pending
-
2022
- 2022-07-04 JP JP2022107500A patent/JP7462338B2/en active Active
-
2024
- 2024-03-14 JP JP2024039547A patent/JP2024061831A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007000985A1 (en) | 2005-06-27 | 2007-01-04 | Kyowa Hakko Kogyo Co., Ltd. | Prophylactic or therapeutic composition for hemoglobinuria or myoglobinuria |
JP2008073007A (en) | 2006-09-25 | 2008-04-03 | Kyowa Hakko Kogyo Co Ltd | Vinegar acidity suppressing method |
JP2011139687A (en) | 2010-01-08 | 2011-07-21 | Kirin Holdings Co Ltd | Highly flavored ornithine-containing alcohol-free malt beverage |
JP2011147419A (en) | 2010-01-25 | 2011-08-04 | Kirin Kyowa Fd Kk | Ornithine-containing instant dried rice gruel |
JP2014054234A (en) | 2012-09-14 | 2014-03-27 | Daicel Corp | Composition containing ornithine and equol |
JP2015050991A (en) | 2013-08-05 | 2015-03-19 | 株式会社ニッセン | Health supplement |
Non-Patent Citations (8)
Title |
---|
Beauty Supplement Drink,Mintel GNPD [online],2013年09月,URL:https://www.gnpd.com,[retrieved on 2023.6.16],ID#2177842 |
Black Sesame & Soybean Milk Shake,Mintel GNPD [online],2011年11月,URL:https://www.gnpd.com,[retrieved on 2023.6.16],ID#1678693 |
Cryo-Anabolic Post-Workout Growth-Inducing Event,Mintel GNPD [online],2008年09月,URL:https://www.gnpd.com,[retrieved on 2023.6.16],ID#966917 |
Meal Replacement Smoothie Assortment,Mintel GNPD [online],2014年11月,URL:https://www.gnpd.com,[retrieved on 2023.6.16],ID#2817545 |
Ornithine & Curcumin with Kuzu Flower Supplement Tablets,Mintel GNPD [online],2009年11月,URL:https://www.gnpd.com,[retrieved on 2023.6.16],ID#1352507 |
Sichuan Mapo Tofu Flavour Cheese,Mintel GNPD [online],2015年04月,URL:https://www.gnpd.com,[retrieved on 2023.6.16],ID#3111793 |
ナメコ菌床栽培における子実体の生育ステージと子実体成分との関係,富山県農林水産総合技術センター森林研究所研究報告,4号,2012年03月,pp.8-14 |
ブナシメジの食味に影響を及ぼす呈味成分の品種間差異,J. Hokkaido For. Prod. Res. Inst.,第19巻, 第1号,2005年,pp.25-30 |
Also Published As
Publication number | Publication date |
---|---|
JP2022121730A (en) | 2022-08-19 |
JP2024061831A (en) | 2024-05-08 |
JP2021050244A (en) | 2021-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2024009190A (en) | Bone fortifier dietary supplements | |
JP5888574B1 (en) | Blood flow improver | |
JP6584270B2 (en) | Blood flow improving composition | |
JP6647809B2 (en) | Retinal protective composition | |
CN108697679B (en) | Amino acid-containing composition | |
JP7462338B2 (en) | Anti-fatigue | |
JP6646369B2 (en) | Anti-fatigue agent | |
JP6742575B2 (en) | Joint function improving composition | |
JP6753618B2 (en) | Composition for suppressing increase in triglyceride in blood | |
JP6841444B2 (en) | Immunostimulant | |
JP6829487B2 (en) | Anti-fatigue | |
JP2017001966A (en) | Blood triglyceride elevation-inhibiting composition | |
JP2020186264A (en) | In-blood neutral fat increase inhibitory composition | |
JP2016216373A (en) | Blood-flow improving agent | |
JP2017002009A (en) | Adjuvant | |
JP2019112470A (en) | Blood flow improver | |
JP7290369B2 (en) | Blood triglyceride elevation suppressing composition | |
JP6838752B2 (en) | Blood flow improving composition | |
JP6736137B2 (en) | Retinal protection composition | |
JP7364252B2 (en) | Retinal protective composition | |
JP6744673B2 (en) | Joint function improving composition | |
JP2022173468A (en) | Bloodstream ameliorating composition | |
JP2023029502A (en) | Blood flow improver | |
JP2023106548A (en) | Composition for suppressing increase in triglyceride in blood | |
JP6612064B2 (en) | Beauty composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220706 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230623 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230802 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230915 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231121 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240119 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240305 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240318 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7462338 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |